Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only Get Premium

KALA Kala Pharmaceuticals Inc

Price (delayed)

$3.64

Market cap

$23.49M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$7.97

Enterprise value

$13.61M

Kala is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of the eye. Kala has applied its AMPPLIFY® mucus-penetrating particle (MPP) Drug Delivery ...

Highlights
The EPS rose by 47% year-on-year and by 21% since the previous quarter
KALA's debt is down by 12% YoY
KALA's quick ratio has plunged by 55% YoY and by 39% from the previous quarter
Kala Pharmaceuticals's equity has shrunk by 54% QoQ and by 14% YoY

Key stats

What are the main financial stats of KALA
Market
Shares outstanding
6.45M
Market cap
$23.49M
Enterprise value
$13.61M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.11
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
Gross profit
$0
Operating income
-$39.31M
Net income
-$35.65M
EBIT
-$30.23M
EBITDA
-$29.63M
Free cash flow
-$27.56M
Per share
EPS
-$7.97
EPS diluted
-$7.97
Free cash flow per share
-$4.34
Book value per share
$0.88
Revenue per share
$0
TBVPS
$7.6
Balance sheet
Total assets
$48.25M
Total liabilities
$42.54M
Debt
$32.35M
Equity
$5.71M
Working capital
$22.74M
Liquidity
Debt to equity
5.67
Current ratio
1.99
Quick ratio
1.84
Net debt/EBITDA
0.33
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-65%
Return on equity
-369.3%
Return on invested capital
-154.9%
Return on capital employed
-119.6%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

KALA stock price

How has the Kala Pharmaceuticals stock price performed over time
Intraday
-0.82%
1 week
4%
1 month
5.35%
1 year
-44.43%
YTD
-47.55%
QTD
-36.47%

Financial performance

How have Kala Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$39.31M
Net income
-$35.65M
Gross margin
N/A
Net margin
N/A
KALA financials
Kala Pharmaceuticals's net income has increased by 10% YoY and by 7% QoQ
KALA's operating income is up by 3.8% YoY and by 2.8% QoQ

Price vs fundamentals

How does KALA's price correlate with its fundamentals
Price vs fundamentals
Earnings waterfall
Price vs fair value

Growth

What is Kala Pharmaceuticals's growth rate over time
KALA growth chart

Valuation

What is Kala Pharmaceuticals stock price valuation
P/E
N/A
P/B
4.11
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Valuation vs average
Price to earnings (P/E)
The EPS rose by 47% year-on-year and by 21% since the previous quarter
Price to book (P/B)
Kala Pharmaceuticals's equity has shrunk by 54% QoQ and by 14% YoY
The price to book (P/B) is 26% higher than the 5-year quarterly average of 3.3 and 15% higher than the last 4 quarters average of 3.6
Price to sales (P/S)

Efficiency

How efficient is Kala Pharmaceuticals business performance
The ROIC has shrunk by 54% YoY and by 9% QoQ
The company's return on assets rose by 5% QoQ and by 2.8% YoY
The return on equity is up by 5% since the previous quarter

Dividends

What is KALA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for KALA.

Financial health

How did Kala Pharmaceuticals financials performed over time
Assets vs liabilities
The total assets is 13% more than the total liabilities
KALA's quick ratio has plunged by 55% YoY and by 39% from the previous quarter
KALA's current ratio has shrunk by 53% YoY and by 36% QoQ
Debt vs equity
The debt to equity has soared by 116% from the previous quarter and by 3.3% YoY
Kala Pharmaceuticals's equity has shrunk by 54% QoQ and by 14% YoY
Balance sheet

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.